Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission

Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene

Giovanna Meloni, Daniela Diverio, Marco Vignetti, Giuseppe Avvisati, Saveria Capria, Maria Concerta Petti, Franco Mandelli, Francesco Lo Coco

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Reverse-transcription polymerase chain reaction (RT-PCR) of the PML/RARα fusion gene may predict relapse in acute promyelocytic leukemia (APL) patients in hematologic complete remission (CR). We have prospectively studied by RT-PCR 15 PML/RARα+ APL patients undergoing autologous bone marrow transplantation (ABMT) in second CR. The median time of first CR duration was 12 months (range, 6 to 40). All patients were reinduced with all-trans retinoic acid (ATRA), followed in 12 of 15 cases by mitoxantrone and Ara-C as consolidation. Fourteen patients received the BAVC (BCNU, Ara- C, m-AMSA, and VP-16) schedule as conditioning regimen. Unpurged marrows were collected immediately before conditioning treatment, analyzed by RT-PCR, and reinfused at median of 2 months (range, 2 to 7) from the achievement of second CR. Seven patients were PCR+ and eight PCR- for PML/RARα in their pretransplant marrows. All seven patients of the former group remained PCR+ during the followup and relapsed at a median time of 5 months (range, 2 to 9) from ABMT and 9 months (range, 4 to 14) from second CR. Of the eight PCR- patients, all remained PCR- during the follow-up controls. One patient relapsed at 10 months from ABMT, one died of a secondary (PML/RARα-) leukemia, and six are in hematologic and molecular remission at a median time of 28 months (range, 15 to 60) after ABMT and 32 months (range, 17 to 62) from second CR. Our results indicate that, in APL patients in second CR, ABMT with PML/RARα- marrow cells is likely to result in prolonged clinical and molecular remissions. Conversely, patients who test PCR+ after reinduction necessitate the use of alternative aggressive approaches, including unrelated allogeneic transplant.

Original languageEnglish
Pages (from-to)1321-1325
Number of pages5
JournalBlood
Volume90
Issue number3
Publication statusPublished - Aug 1 1997

Fingerprint

Acute Promyelocytic Leukemia
Autologous Transplantation
Gene Fusion
Polymerase chain reaction
Residual Neoplasm
Transcription
Bone Marrow Transplantation
Reverse Transcription
Bone
Fusion reactions
Genes
Polymerase Chain Reaction
Cytarabine
Amsacrine
Carmustine
Mitoxantrone
Transplants
Bone Marrow
Etoposide
Tretinoin

ASJC Scopus subject areas

  • Hematology

Cite this

Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission : Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene. / Meloni, Giovanna; Diverio, Daniela; Vignetti, Marco; Avvisati, Giuseppe; Capria, Saveria; Petti, Maria Concerta; Mandelli, Franco; Lo Coco, Francesco.

In: Blood, Vol. 90, No. 3, 01.08.1997, p. 1321-1325.

Research output: Contribution to journalArticle

Meloni, Giovanna ; Diverio, Daniela ; Vignetti, Marco ; Avvisati, Giuseppe ; Capria, Saveria ; Petti, Maria Concerta ; Mandelli, Franco ; Lo Coco, Francesco. / Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission : Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene. In: Blood. 1997 ; Vol. 90, No. 3. pp. 1321-1325.
@article{ff2c48213db24bb0b368c2ab3cccd599,
title = "Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene",
abstract = "Reverse-transcription polymerase chain reaction (RT-PCR) of the PML/RARα fusion gene may predict relapse in acute promyelocytic leukemia (APL) patients in hematologic complete remission (CR). We have prospectively studied by RT-PCR 15 PML/RARα+ APL patients undergoing autologous bone marrow transplantation (ABMT) in second CR. The median time of first CR duration was 12 months (range, 6 to 40). All patients were reinduced with all-trans retinoic acid (ATRA), followed in 12 of 15 cases by mitoxantrone and Ara-C as consolidation. Fourteen patients received the BAVC (BCNU, Ara- C, m-AMSA, and VP-16) schedule as conditioning regimen. Unpurged marrows were collected immediately before conditioning treatment, analyzed by RT-PCR, and reinfused at median of 2 months (range, 2 to 7) from the achievement of second CR. Seven patients were PCR+ and eight PCR- for PML/RARα in their pretransplant marrows. All seven patients of the former group remained PCR+ during the followup and relapsed at a median time of 5 months (range, 2 to 9) from ABMT and 9 months (range, 4 to 14) from second CR. Of the eight PCR- patients, all remained PCR- during the follow-up controls. One patient relapsed at 10 months from ABMT, one died of a secondary (PML/RARα-) leukemia, and six are in hematologic and molecular remission at a median time of 28 months (range, 15 to 60) after ABMT and 32 months (range, 17 to 62) from second CR. Our results indicate that, in APL patients in second CR, ABMT with PML/RARα- marrow cells is likely to result in prolonged clinical and molecular remissions. Conversely, patients who test PCR+ after reinduction necessitate the use of alternative aggressive approaches, including unrelated allogeneic transplant.",
author = "Giovanna Meloni and Daniela Diverio and Marco Vignetti and Giuseppe Avvisati and Saveria Capria and Petti, {Maria Concerta} and Franco Mandelli and {Lo Coco}, Francesco",
year = "1997",
month = "8",
day = "1",
language = "English",
volume = "90",
pages = "1321--1325",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission

T2 - Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene

AU - Meloni, Giovanna

AU - Diverio, Daniela

AU - Vignetti, Marco

AU - Avvisati, Giuseppe

AU - Capria, Saveria

AU - Petti, Maria Concerta

AU - Mandelli, Franco

AU - Lo Coco, Francesco

PY - 1997/8/1

Y1 - 1997/8/1

N2 - Reverse-transcription polymerase chain reaction (RT-PCR) of the PML/RARα fusion gene may predict relapse in acute promyelocytic leukemia (APL) patients in hematologic complete remission (CR). We have prospectively studied by RT-PCR 15 PML/RARα+ APL patients undergoing autologous bone marrow transplantation (ABMT) in second CR. The median time of first CR duration was 12 months (range, 6 to 40). All patients were reinduced with all-trans retinoic acid (ATRA), followed in 12 of 15 cases by mitoxantrone and Ara-C as consolidation. Fourteen patients received the BAVC (BCNU, Ara- C, m-AMSA, and VP-16) schedule as conditioning regimen. Unpurged marrows were collected immediately before conditioning treatment, analyzed by RT-PCR, and reinfused at median of 2 months (range, 2 to 7) from the achievement of second CR. Seven patients were PCR+ and eight PCR- for PML/RARα in their pretransplant marrows. All seven patients of the former group remained PCR+ during the followup and relapsed at a median time of 5 months (range, 2 to 9) from ABMT and 9 months (range, 4 to 14) from second CR. Of the eight PCR- patients, all remained PCR- during the follow-up controls. One patient relapsed at 10 months from ABMT, one died of a secondary (PML/RARα-) leukemia, and six are in hematologic and molecular remission at a median time of 28 months (range, 15 to 60) after ABMT and 32 months (range, 17 to 62) from second CR. Our results indicate that, in APL patients in second CR, ABMT with PML/RARα- marrow cells is likely to result in prolonged clinical and molecular remissions. Conversely, patients who test PCR+ after reinduction necessitate the use of alternative aggressive approaches, including unrelated allogeneic transplant.

AB - Reverse-transcription polymerase chain reaction (RT-PCR) of the PML/RARα fusion gene may predict relapse in acute promyelocytic leukemia (APL) patients in hematologic complete remission (CR). We have prospectively studied by RT-PCR 15 PML/RARα+ APL patients undergoing autologous bone marrow transplantation (ABMT) in second CR. The median time of first CR duration was 12 months (range, 6 to 40). All patients were reinduced with all-trans retinoic acid (ATRA), followed in 12 of 15 cases by mitoxantrone and Ara-C as consolidation. Fourteen patients received the BAVC (BCNU, Ara- C, m-AMSA, and VP-16) schedule as conditioning regimen. Unpurged marrows were collected immediately before conditioning treatment, analyzed by RT-PCR, and reinfused at median of 2 months (range, 2 to 7) from the achievement of second CR. Seven patients were PCR+ and eight PCR- for PML/RARα in their pretransplant marrows. All seven patients of the former group remained PCR+ during the followup and relapsed at a median time of 5 months (range, 2 to 9) from ABMT and 9 months (range, 4 to 14) from second CR. Of the eight PCR- patients, all remained PCR- during the follow-up controls. One patient relapsed at 10 months from ABMT, one died of a secondary (PML/RARα-) leukemia, and six are in hematologic and molecular remission at a median time of 28 months (range, 15 to 60) after ABMT and 32 months (range, 17 to 62) from second CR. Our results indicate that, in APL patients in second CR, ABMT with PML/RARα- marrow cells is likely to result in prolonged clinical and molecular remissions. Conversely, patients who test PCR+ after reinduction necessitate the use of alternative aggressive approaches, including unrelated allogeneic transplant.

UR - http://www.scopus.com/inward/record.url?scp=0030741745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030741745&partnerID=8YFLogxK

M3 - Article

VL - 90

SP - 1321

EP - 1325

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -